HaiHe's listing recipe

Why Huagai is backing oncology play HaiHe’s planned IPO

While a recent mega-round raised by HaiHe could position the Shanghai-based company to go public this year, lead investor Huagai Capital is not looking for an exit at least until the company’s first products hit the market.

Shanghai HaiHe Biopharma Co. Ltd., which expects its February $147 million B round to provide at least two years of runway, is considering listing in Hong

Read the full 620 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE